Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)

Table 2 Vaccine immune response monitoring in previously infected and not previously infected cohorts of healthcare providers

	Median (IR) BAU/mL
	T0	T1	T2	T3	T6	T9	T boost
Previously infected subjects	35.6	> 2500.0	> 2500.0	> 2500.0	2098.0	1212.5	> 2500.0
	(20.4–91.4)				(1565.5–>2500.0)	(957.2–2423.3)
	n = 27	n = 27	n = 27	n = 27	n = 27	n = 26	n = 5
Not previously infected subjects	< 0.4	26.5	> 2500.0	853.4	574.0	381.0	> 2500.0
		(9.4–68.5)	(2020.0–>2500.0)	(514.9–1252.0)	(363.5–814.8)	(255.3–579.4)
	n = 123	n = 123	n = 123	n = 123	n = 123	n = 62	n = 14

Previously infected subjects = subjects previously infected with SARS-CoV-2, Not previously infected subjects = subjects not infected with SARS-CoV-2, n = number of subjects, median = median of anti-SARS-CoV-2 S titers, IR = Interquartile Range of anti-SARS-CoV-2 S titers, For previously infected subjects: T0 = baseline pre-vaccination after SARS-CoV-2 infection, T1 = 8 days after the unique dose, T2 = 1 month after the unique dose, T3 = 3 months after the unique dose, T6 = 6 months after the unique dose, T9 = 9 months after the unique dose, T boost = 8 days after the administration of a further boost dose. For not infected subjects: T0 = baseline pre-vaccination, T1 = 20 days after the first dose, T2 = 8 days after the second dose, T3 = 3 months after the second dose, T6 = 6 months after the second dose, T9 = 9 months after the second dose, T boost = 8 days after the administration of boost dose

ISSN: 1750-9378